Analysts estimate that Coherus BioSciences will report an earnings per share (EPS) of $-0.34. Investors in Coherus BioSciences are eagerly awaiting the company's announcement, hoping for news of ...
Coherus BioSciences, Inc. announced the completion of its strategic transformation to focus on innovative oncology during Q2 2025, highlighting encouraging Phase 1b data for CHS-114, an anti-CCR8 ...
– Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L ...
COHERUS BIOSCIENCES ($CHRS) is expected to release its quarterly earnings data on Monday, May 12th after market close, per Finnhub. Analysts are expecting revenue of ...
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market ...
A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time ...
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA ® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI ® net sales ...
Detailed price information for Coherus Oncology Inc (CHRS-Q) from The Globe and Mail including charting and trades.
REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Coherus BioSciences Inc. (CHRS) on Monday reported a loss of $56.6 million in its first quarter. The Redwood City, California-based company said ...
On October 27, 2023, the FDA approved LOQTORZI™ (toripalimab-tpzi) in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced ...
Coherus BioSciences (NASDAQ:CHRS) is gearing up to announce its quarterly earnings on Thursday, 2025-11-06. Here's a quick overview of what investors should know before the release. Analysts are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results